SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-070503
Filing Date
2024-06-12
Accepted
2024-06-11 17:56:21
Documents
14
Period of Report
2024-06-10
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm249625d6_8k.htm   iXBRL 8-K 49494
2 EXHIBIT 3.1 tm249625d6_ex3-1.htm EX-3.1 7377
  Complete submission text file 0001104659-24-070503.txt   234938

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btai-20240610.xsd EX-101.SCH 3048
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20240610_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20240610_pre.xml EX-101.PRE 22381
17 EXTRACTED XBRL INSTANCE DOCUMENT tm249625d6_8k_htm.xml XML 3684
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 241036975
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)